A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
← catalyst calendarNCT07005128 · readout in 869 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →. With AstraZeneca.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
330estimated
Sites
164
Countries
Argentina, Australia, Austria +23
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-18 | actual | When the study began enrolling |
| Primary completion | 2029-01-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-07-15 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Small-cell Lung Cancer
- Extensive Stage Small-cell Lung Cancer
Interventions
- Drug: Tarlatamab — also filed as AMG 757, Imdelltra
- Drug: Durvalumab
- Drug: Carboplatin
- Drug: Etoposide
Primary outcomes
what the primary-completion date above is the date OFOverall Survival (OS)
measured Up to approximately 3.5 years
Progression free survival (PFS) (Blinded Independent Central Review [BICR] Assessed)
measured Up to approximately 3.5 years
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed